BNP Paribas Asset Management
IMVT icon

BNP Paribas Asset Management’s Immunovant IMVT Stock Holding History

BNP Paribas Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.8K Sell
903
-430
-32% -$13.1K ﹤0.01% 1890
2026
Q1 		$33.1K Buy
1,333
+508
+62% +$13.2K ﹤0.01% 1876
2025
Q4 		$21K Buy
825
+351
+74% +$7.83K ﹤0.01% 1945
2025
Q3 		$8K Hold
474
– – ﹤0.01% 1697
2025
Q2 		$8K Buy
+474
New +$7.17K ﹤0.01% 1850

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Asset Management's IMVT Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Immunovant (IMVT) stake by 32% in Q2 2026, selling an estimated $13.1K and leaving 903 shares worth $34.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

BNP Paribas Asset Management first reported a position in IMVT in Q2 2025 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • BNP Paribas Asset Management held 903 shares of Immunovant worth $34.8K as of Q2 2026.
  • BNP Paribas Asset Management sold 430 Immunovant shares in Q2 2026, an estimated $13.1K.
  • Immunovant made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1890 holding.
  • BNP Paribas Asset Management first reported a position in Immunovant in Q2 2025 and has held it in 5 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.